StockData
QIAGEN N.V. logo

QIAGEN N.V. (QGEN) stock

QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 10/30
$49.56−0.19 (-0.38%)

Close on Nov 18, 2026Market cap $10.75BP/E 25.5Yield 0.50%

Qiagen operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was $465.85M, up 376.8% from the year before. Over ten years it grew 10.0% a year on average. The highest annual figure on record is $630.08M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$465.85M+376.8%
FY2024Dec 31, 2024$97.71M-76.2%
FY2023Dec 31, 2023$409.94M-22.9%
FY2022Dec 31, 2022$531.46M-15.7%
FY2021Dec 31, 2021$630.08M+63.1%
FY2020Dec 31, 2020$386.43M–
FY2019Dec 31, 2019-$26.14M-109.8%
FY2018Dec 31, 2018$266.58M+73.8%
FY2017Dec 31, 2017$153.42M+55.2%
FY2016Dec 31, 2016$98.83M-44.9%
FY2015Dec 31, 2015$179.50M+11.0%
FY2014Dec 31, 2014$161.69M+155.3%
FY2013Dec 31, 2013$63.33M-62.7%
FY2012Dec 31, 2012$169.81M+70.5%
FY2011Dec 31, 2011$99.59M-47.2%
FY2010Dec 31, 2010$188.54M+4.6%
FY2009Dec 31, 2009$180.21M+23.7%
FY2008Dec 31, 2008$145.66M–

More Qiagen figures

See a number that looks wrong?